Lenalidomide versus Thalidomide or Bortezomib as maintenance regimen for non-transplant patients with multiple myeloma: multi-center real world experiences in China

被引：0

作者：

Zhuang, Zhe ^{[1
]}

Shi, Lei ^{[2
]}

Tian, Ying ^{[3
]}

Zou, Dongmei ^{[4
]}

Feng, Ru ^{[5
]}

Dong, Fei ^{[6
]}

Ma, Yanping ^{[7
]}

Yu, Hong ^{[8
]}

Tian, Wei-wei ^{[9
]}

Liu, Shuangjiao ^{[1
]}

Ma, Liang-Ming ^{[10
]}

Fu, Rong ^{[8
]}

Jing, Hongmei ^{[6
]}

Liu, Hui

Sun, Wanling ^{[4
]}

Chen, Wenming ^{[3
]}

Wu, Yin ^{[3
]}

Bao, Li ^{[2
]}

Zhuang, Junling ^{[1
]}

机构：

[1] Chinese Acad Med Sci, Dept Hematol, Peking Union Med Coll Hosp, Beijing, Peoples R China

[2] Beijing Jishuitan Hosp, Dept Hematol, Beijing, Peoples R China

[3] Capital Med Univ, Dept Hematol, Beijing Chao Yang Hosp, Beijing, Peoples R China

[4] Capital Med Univ, Dept Hematol, Xuanwu Hosp, Beijing, Peoples R China

[5] Chinese Acad Med Sci, Beijing Hosp, Inst Geriatr Med, Dept Hematol, Beijing, Peoples R China

[6] Peking Univ Third Hosp, Dept Hematol, Beijing, Peoples R China

[7] Shanxi Med Univ, Dept Hematol, Hosp 2, Taiyuan, Peoples R China

[8] Tianjin Med Univ, Dept Hematol, Gen Hosp, Tianjin, Peoples R China

[9] Shanxi Med Univ, Dept Hematol, Shanxi Bethune Hosp, Taiyuan, Peoples R China

[10] Shanxi Med Univ, Hosp 2, Dept Hematol, Taiyuan, Peoples R China

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2021年 / 21卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-141

引用

页码：S112 / S113

页数：2

共 50 条

[41] Bayesian Network Meta-Analysis (NMA): Safety of Bortezomib, Thalidomide or Lenalidomide Containing Regimens for Transplant Ineligible Multiple Myeloma (MM) Patients
Satta, Toshihisa
Yamaguchi, Norihiro
Malone, Adriana
Talcott, James
Chari, Ajai
BLOOD, 2015, 126 (23)
[42] An Adjusted Treatment Comparison of Bortezomib/Cyclophosphamide/Dexamethasone and Bortezomib/Thalidomide/Dexamethasone from Real-World Data in Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant-Eligible
Mehra, Maneesha
Cote, Sarah
Kampfenkel, Tobias
Nair, Sandhya
BLOOD, 2019, 134
[43] Thalidomide and Dexamethasone Maintenance after Autologous Stem Cell Transplantation in Newly Diagnosed Korean Multiple Myeloma Patients: A Prospective Multi-Center Study in Asia
Kim, Sang-A
Yoon, Sung-Soo
Koh, Youngil
Shin, Dong-Yeop
Kim, Jin Seok
Kim, Kihyun
Min, Chang-Ki
Eom, Hyeon-Seok
Lee, Je-Jung
Lee, Jeong-Ok
Bang, Soo-Mee
BLOOD, 2017, 130
[44] A CANADIAN COST ANALYSIS COMPARING THE USE OF BORTEZOMIB OR LENALIDOMIDE AS MAINTENANCE THERAPIES IN MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANT
LeBlanc, R.
Tay, J.
Hollmann, S.
Shustik, J.
VALUE IN HEALTH, 2014, 17 (03) : A77 - A77
[45] A Phase 2 Multi-Center, Open Label Study of Isatuximab Added to Standard Cybord Induction and Lenalidomide Maintenance Treatments in Newly Diagnosed, Transplant Eligible Multiple Myeloma
Kotb, Rami
Gul, Engin
Reece, Donna E.
BLOOD, 2021, 138
[46] Real-World Outcomes for Maintenance Treatment Sequencing after Receiving Lenalidomide, Bortezomib, and Dexamethasone Induction in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Followed By Autologous Stem Cell Transplant (ASCT)
Fonseca, Rafael
Parikh, Kejal
Ung, Brian
Ni, Quanhong
Abouzaid, Safiya
Agarwal, Amit
BLOOD, 2017, 130
[47] Lenalidomide Maintenance for Patients with Newly Diagnosed Multiple Myeloma Post Autologous Stem Cell Transplant: A Comparison of Real-World Treatment Outcomes and Costs
Hari, Parameswaran
Ung, Brian
Abouzaid, Safiya
Ni, Quanhong
Parikh, Kejal
Agarwal, Amit
BLOOD, 2017, 130
[48] Consolidation therapy with bortezomib/lenalidomide/dexamethasone versus bortezomib/dexamethasone after a dexamethasone-based induction regimen in patients with multiple myeloma: A randomized phase III trial
Fonseca, Rafael
Rajkumar, S. Vincent
CLINICAL LYMPHOMA & MYELOMA, 2008, 8 (05): : 315 - 317
[49] First-line therapy with bendamustine/prednisone/bortezomib-A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients
Knauf, Wolfgang
Dingeldein, Gerrit
Schlag, Rudolf
Welslau, Manfred
Moehler, Thomas
Terzer, Tobias
Walter, Sarah
Habermehl, Christina
Kunz, Christina
Goldschmidt, Hartmut
Raab, Marc-Steffen
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (02) : 116 - 125
[50] Real-World Outcomes for Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone, or Bortezomib and Dexamethasone: An Enhanced Electronic Health Records Database Analysis
Chari, Ajai
Ung, Brian
Tian, Marc
Agarwal, Amit
Parikh, Kejal
BLOOD, 2018, 132

← 1 2 3 4 5 →